Across TCGA pan-cancer cohorts, TRAV18 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRAV18 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TRAV18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV18 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA and UCEC are the cancer types where TRAV18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.141	0.655	.002	27	view →
UCEC	DFS	Median	III,IV	1.000	0.539	.042	10	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TRAV18 tumor-vs-normal RNA expression · all TRAV18 data types